USPTO serial 98300221
ARUP INSTITUTE FOR RESEARCH AND INNOVATION IN DIAGNOSTIC AND PRECISION MEDICINE
Reviewed by CopyMark Law Group
Status 732Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- LEASER, ANDREW C
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with ARUP INSTITUTE FOR RESEARCH AND INNOVATION IN DIAGNOSTIC AND PRECISION MEDICINE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $947*
Plus Government fees of $450
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Salt Lake City, UT, US
Salt Lake City, UT, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lester K. Essig
Lester K. Essig Ray Quinney & Nebeker36 South State StreetSuite 1400Salt Lake City, UT 84111Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 041 | Educational services, namely, arranging and conducting classes, seminars, conferences, colloquiums, workshops and panel discussions, and distributing educational materials, brochures and reports in connection therewith, in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, immunofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, and health care. | ACTIVE | — |
| 042 | Clinical laboratory research services, reference laboratory research services, diagnostic laboratory research services, medical laboratory services, and providing medical laboratory information online over the global communications network, all in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, gene therapy, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, inununofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, and health care; clinical laboratory research services, reference laboratory research services, dissection laboratory research services, diagnostic laboratory research services, medical laboratory services, veterinary laboratory services, and medical and scientific research, namely, collecting, processing, treating, freezing, staining, dissecting, analyzing, screening, testing, typing and storing of biological substances and human and animal tissue, blood, blood components, cells, stems cells, abnormal cells, chromosomes and nucleic acid; scientific laboratory services, namely, development, improvement, evaluation, analysis and application of clinical laboratory tests and diagnostics in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, immunofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, and health care; and medical research in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, immunofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, and health care. | ACTIVE | — |
| 044 | Medical testing services in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, immunofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, and health care; and providing medical information online over a global communications network in the fields of pathology, clinical pathology, anatomic pathology, histopathology, histology, infectious diseases, disease pathology, infectious disease pathology, staining analysis, virology, hematopathology, hematology, proteomics, hemostasis, thrombosis, flow analysis, flow cytometry, capillary electrophoresis, genetics, molecular genetics, biochemical genetics, genetic diseases, gene identification, gene sequencing, nucleotide sequencing, genotypic identification, phenotypic identification, probe synthesis, mass spectrometry, tandem mass spectrometry, molecular testing, molecular diagnostics, molecular evaluation, cytopathology, cytology, cytogenetics, oncology, tumor detection, tumor markers, tumor diagnostics, mutation detection, mutation analysis, morphologic change, immunopathology, immunology, immunohematology, immunohistochemical staining, immunofluorescence, autoimmune disorders, microbiology, serology, microbial serology, endocrinology, clinical chemistry, toxicology, clinical toxicology, toxins, pharmacogenomics, therapeutic drugs, transplantation pathology, surgical pathology, autopsy pathology, metabolics, metabolic status, nutritional status, microscopy, core lab testing, engineering analysis, laboratory automation, medical informatics, and health care. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ARUP Laboratories, Inc.
- Other trademarks owned by ARUP Laboratories, Inc.
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ARUP INSTITUTE FOR RESEARCH AND INNOVATION IN DIAGNOSTIC AND PRECISION MEDICINE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 26, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 25, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 25, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 25, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 28, 2026 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Apr 28, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 28, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 28, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 18, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 17, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 17, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 17, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 26, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 25, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Sep 25, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Sep 25, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 25, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 28, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 28, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 22, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 3, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 2, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 2, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 2, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 3, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Oct 3, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jul 5, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 5, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 5, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 2, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 1, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 5, 2023 | NWAP | NEW APPLICATION ENTERED | — |